Clinical Trials, Research, and Investigational Drug Facilitation and Evaluation
Trial foundations
Understand phases: I (safety/dose), II (activity/screening), III (comparative confirmatory), IV (postmarketing). Know endpoints (OS, PFS, ORR, DFS, QoL), randomization, blinding, allocation concealment, power, alpha, confidence intervals, intention-to-treat (ITT), per-protocol, interim analyses, and DSMB roles. Research pharmacists ensure protocol adherence, informed consent, investigational product accountability, blinding integrity, and adverse event reporting.
Concepts to master
GCP, IRB oversight, eligibility criteria, protocol deviations, SAE timelines, unblinding procedures, drug storage/temperature logs, randomization codes, and sponsor-investigator responsibilities. Distinguish superiority from noninferiority; a noninferiority margin must be prespecified. Understand type I/II error and why ITT preserves randomization.
Traps
Phase I is not designed to prove efficacy. Phase II is not confirmatory. Do not unblind casually. Do not report an SAE only at the next monitor visit. Do not confuse statistical significance with clinical benefit. Do not enroll a patient who does not meet eligibility because “the protocol can be amended.” Do not break randomization blind to manage a toxicity unless the protocol requires it.
Worked example
In a noninferiority phase III trial, the margin and analysis populations are prespecified. If the CI excludes the margin and ITT and per-protocol agree, noninferiority is supported; if not, do not claim equivalence.
Rule of thumb: follow the protocol, document deviations, protect blinding, and report safety events promptly.